The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Hoffmann-La Roche
Swiss healthcare company
-
Biogen
American multinational biotechnology company
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- FDA granted 510(k) clearance for a new panel developed by Hoffmann-La Roche.
- The FDA reversed its decision regarding a gene therapy application from uniQure N.V.
- A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.